Beta Bionics (NASDAQ:BBNX) Stock Rating Lowered by Bank of America

Beta Bionics (NASDAQ:BBNX) was downgraded by equities research analysts at Bank of America from a “buy” rating to a “neutral” rating in a report issued on Friday, MarketBeat.com reports.

Several other equities research analysts have also weighed in on BBNX. Robert W. Baird set a $28.00 target price on shares of Beta Bionics in a report on Tuesday, December 16th. Piper Sandler restated an “overweight” rating and issued a $32.00 price target (up from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Wall Street Zen raised shares of Beta Bionics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 1st. Lake Street Capital reiterated a “buy” rating and issued a $35.00 target price on shares of Beta Bionics in a research note on Wednesday, October 29th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $31.00 target price (up from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $30.20.

Beta Bionics Price Performance

Beta Bionics stock opened at $20.14 on Friday. The business has a 50 day simple moving average of $29.28 and a 200 day simple moving average of $22.32. The company has a market capitalization of $886.76 million and a PE ratio of -4.61. Beta Bionics has a one year low of $8.89 and a one year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.The firm had revenue of $27.25 million for the quarter, compared to analysts’ expectations of $23.92 million.

Insider Activity at Beta Bionics

In related news, insider Mike Mensinger sold 2,200 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the sale, the insider owned 80,752 shares of the company’s stock, valued at $2,430,635.20. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 35,302 shares of company stock worth $1,036,449.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Beta Bionics in the 1st quarter valued at $95,000. Goldman Sachs Group Inc. bought a new position in Beta Bionics in the first quarter valued at about $715,000. Woodline Partners LP bought a new position in Beta Bionics in the first quarter valued at about $1,530,000. Strs Ohio acquired a new stake in Beta Bionics in the first quarter worth about $29,000. Finally, Rhumbline Advisers bought a new stake in Beta Bionics during the 1st quarter worth about $158,000.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Preliminary Q4 topline and revenue guidance: Beta Bionics announced preliminary, unaudited Q4 2025 topline growth and issued revenue guidance of roughly $32.0M versus a ~ $29.0M consensus, signaling stronger-than-expected sales momentum. GlobeNewswire – Q4 Topline Results
• Neutral Sentiment: Company release is preliminary/unaudited and EPS guidance was not specified — investors must await audited results and detailed metrics to confirm margin and profitability trends. Finanznachrichten – Preliminary Results
• Negative Sentiment: Deceleration in new patient starts: Reports highlighted a slowdown in new patient onboarding for the iLet system, which traders flagged as a demand-growth warning and a primary reason shares tumbled. Investing.com – New Patient Starts Slow
• Negative Sentiment: Analyst downgrades and valuation concerns: Multiple analysts moved to neutral/hold citing a premium valuation alongside slowing new-patient growth (Bank of America shifted to Neutral with a ~$28 PT), increasing selling pressure. DrugDeliveryBusiness – Analyst Downgrades TipRanks – Valuation & Growth
• Negative Sentiment: Insider selling: A named insider sold shares in early January (disclosed filings show several recent sales), which can weigh on sentiment when combined with downgrades and slowing customer adds. MarketBeat – Insider Trades

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.